Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

计划入组 92 人 · 首次发布于 2001 年 8 月 31 日

Vytorin Reexamination Study (0653A-174)

计划入组 2,089 人 · 首次发布于 2010 年 2 月 18 日

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

计划入组 36 人 · 首次发布于 2020 年 12 月 21 日

PHI-201

PHI-501

PHI-101

C₁₉H₁₉FN₄O₂S

Molecule X LLC

Mexico

X-Pert-Med GmbH

Germany

SFJ Pharmaceuticals X, LTD.

AI Model Trained on DNA Creates 16 Novel Viruses, Raising Both Therapeutic Promise and Biosecurity Alarms

CARB-X Awards $1.1 Million to Phiogen for Novel Bacteriophage Treatment Against Drug-Resistant E. coli Bloodstream Infections

Pharos iBio's PHI-101 Demonstrates Promising Complete Response in AML Phase 1 Trial